NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Fundamental Analysis
Europe - FRA:NP5 - IT0004147952 - Common Stock
15.14 EUR
-0.36 (-2.32%)
Taking everything into account, NP5 scores 6 out of 10 in our fundamental rating. NP5 was compared to 53 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of NP5 get a neutral evaluation. Nothing too spectacular is happening here. NP5 is valued quite expensive, but it does show an excellent growth. This makes NP5 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year NP5 was profitable.
In the past year NP5 has reported a negative cash flow from operations.
In the past 5 years NP5 reported 4 times negative net income.
In the past 5 years NP5 always reported negative operating cash flow.
1.2 Ratios
NP5 has a Return On Assets of 24.79%. This is amongst the best in the industry. NP5 outperforms 100.00% of its industry peers.
With an excellent Return On Equity value of 1086.63%, NP5 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of NP5 (47.97%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.79% | ||
| ROE | 1086.63% | ||
| ROIC | 47.97% |
ROA(3y)-28.32%
ROA(5y)-31.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 30.83%, NP5 belongs to the best of the industry, outperforming 94.34% of the companies in the same industry.
With an excellent Operating Margin value of 50.93%, NP5 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Gross Margin, with a value of 98.26%, NP5 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
NP5's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 50.93% | ||
| PM (TTM) | 30.83% | ||
| GM | 98.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y4.26%
2. Health
2.1 Basic Checks
NP5 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, NP5 has more shares outstanding
NP5 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NP5 has been reduced compared to a year ago.
2.2 Solvency
NP5 has an Altman-Z score of 6.42. This indicates that NP5 is financially healthy and has little risk of bankruptcy at the moment.
NP5 has a Altman-Z score of 6.42. This is amongst the best in the industry. NP5 outperforms 88.68% of its industry peers.
A Debt/Equity ratio of 25.32 is on the high side and indicates that NP5 has dependencies on debt financing.
NP5's Debt to Equity ratio of 25.32 is on the low side compared to the rest of the industry. NP5 is outperformed by 83.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 25.32 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.42 |
ROIC/WACC6.45
WACC7.44%
2.3 Liquidity
NP5 has a Current Ratio of 2.60. This indicates that NP5 is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.60, NP5 belongs to the best of the industry, outperforming 84.91% of the companies in the same industry.
NP5 has a Quick Ratio of 2.60. This indicates that NP5 is financially healthy and has no problem in meeting its short term obligations.
NP5 has a Quick ratio of 2.60. This is amongst the best in the industry. NP5 outperforms 86.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
NP5 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 232.04%, which is quite impressive.
The Revenue has grown by 467.41% in the past year. This is a very strong growth!
NP5 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.83% yearly.
EPS 1Y (TTM)232.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)467.41%
Revenue growth 3Y107.38%
Revenue growth 5Y48.83%
Sales Q2Q%249.22%
3.2 Future
The Earnings Per Share is expected to grow by 44.85% on average over the next years. This is a very strong growth
NP5 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.60% yearly.
EPS Next Y-231.2%
EPS Next 2Y-84.82%
EPS Next 3Y-35.68%
EPS Next 5Y44.85%
Revenue Next Year-67.36%
Revenue Next 2Y-49.49%
Revenue Next 3Y-35.39%
Revenue Next 5Y31.6%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
NP5 is valuated reasonably with a Price/Earnings ratio of 11.13.
Based on the Price/Earnings ratio, NP5 is valued a bit cheaper than 79.25% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.83. NP5 is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for NP5. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.13 | ||
| Fwd PE | N/A |
4.2 Price Multiples
NP5's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.17 |
4.3 Compensation for Growth
NP5 has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as NP5's earnings are expected to decrease with -35.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.82%
EPS Next 3Y-35.68%
5. Dividend
5.1 Amount
No dividends for NP5!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:NP5 (11/7/2025, 7:00:00 PM)
15.14
-0.36 (-2.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners8.29%
Inst Owner ChangeN/A
Ins Owners10.76%
Ins Owner ChangeN/A
Market Cap302.19M
Revenue(TTM)51.39M
Net Income(TTM)15.84M
Analysts85
Price Target19.92 (31.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.99%
PT rev (3m)9.13%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)33.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)42.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.13 | ||
| Fwd PE | N/A | ||
| P/S | 5.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 207.27 | ||
| P/tB | 207.27 | ||
| EV/EBITDA | 13.17 |
EPS(TTM)1.36
EY8.98%
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS2.57
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.79% | ||
| ROE | 1086.63% | ||
| ROCE | 64.78% | ||
| ROIC | 47.97% | ||
| ROICexc | 63.39% | ||
| ROICexgc | 63.39% | ||
| OM | 50.93% | ||
| PM (TTM) | 30.83% | ||
| GM | 98.26% | ||
| FCFM | N/A |
ROA(3y)-28.32%
ROA(5y)-31.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y4.26%
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 25.32 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.4 | ||
| Cap/Depr | 6.77% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 13.81 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z | 6.42 |
F-Score6
WACC7.44%
ROIC/WACC6.45
Cap/Depr(3y)7.05%
Cap/Depr(5y)9.34%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)232.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-231.2%
EPS Next 2Y-84.82%
EPS Next 3Y-35.68%
EPS Next 5Y44.85%
Revenue 1Y (TTM)467.41%
Revenue growth 3Y107.38%
Revenue growth 5Y48.83%
Sales Q2Q%249.22%
Revenue Next Year-67.36%
Revenue Next 2Y-49.49%
Revenue Next 3Y-35.39%
Revenue Next 5Y31.6%
EBIT growth 1Y325.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-151.15%
EBIT Next 3Y-30.19%
EBIT Next 5Y37.52%
FCF growth 1Y-73.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.71%
OCF growth 3YN/A
OCF growth 5YN/A
NEWRON PHARMACEUTICALS SPA / NP5.DE FAQ
Can you provide the ChartMill fundamental rating for NEWRON PHARMACEUTICALS SPA?
ChartMill assigns a fundamental rating of 6 / 10 to NP5.DE.
Can you provide the valuation status for NEWRON PHARMACEUTICALS SPA?
ChartMill assigns a valuation rating of 3 / 10 to NEWRON PHARMACEUTICALS SPA (NP5.DE). This can be considered as Overvalued.
How profitable is NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?
NEWRON PHARMACEUTICALS SPA (NP5.DE) has a profitability rating of 6 / 10.
What is the expected EPS growth for NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?
The Earnings per Share (EPS) of NEWRON PHARMACEUTICALS SPA (NP5.DE) is expected to decline by -231.2% in the next year.